PharmaBlock Sciences (Nanjing), Inc.

Shenzhen Stock Exchange 300725.SZ

PharmaBlock Sciences (Nanjing), Inc. Gross Profit Margin for the year ending December 31, 2023: 42.52%

PharmaBlock Sciences (Nanjing), Inc. Gross Profit Margin is 42.52% for the year ending December 31, 2023, a -6.50% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

PharmaBlock Sciences (Nanjing), Inc. Gross Profit Margin for the year ending December 31, 2022 was 45.48%, a -5.51% change year over year.
PharmaBlock Sciences (Nanjing), Inc. Gross Profit Margin for the year ending December 31, 2021 was 48.13%, a 5.10% change year over year.
PharmaBlock Sciences (Nanjing), Inc. Gross Profit Margin for the year ending December 31, 2020 was 45.79%, a -11.25% change year over year.
PharmaBlock Sciences (Nanjing), Inc. Gross Profit Margin for the year ending December 31, 2019 was 51.59%, a -10.77% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Shenzhen Stock Exchange: 300725.SZ

PharmaBlock Sciences (Nanjing), Inc.

CEO	Dr. Minmin Yang Ph.D.
IPO Date	Nov. 10, 2017
Location	China
Headquarters	10 Xuefu Road
Employees	2,455
Sector	Health Care
Industries Pharmaceuticals Chemicals & Advanced Materials Petrochemicals

Description

PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial production. It primarily businesses include building blocks collection, supplying from discovery, development to commercial; building blocks driven libraries for drug discovery; development and manufacturing of RSMs, intermediates, APIs, and drug products for drug development and commercial. The company was founded in 2006 and is based in Nanjing, the People's Republic of China.

Key trends

Past 5 years